{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:29:00Z","timestamp":1791872940996,"version":"4.3.4"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This Mendelian Randomization (MR) study aims to explore the potential bidirectional causal relationship between Inflammatory Bowel Disease (IBD) and Breast Cancer (BC).<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold> We utilized genetic instruments from the summary statistics of genome-wide association studies (GWAS) on IBD among individuals of European ancestry (12,882 cases and 21,770 controls) to investigate the association with breast cancer (14,910 cases and 17,588 controls) and <jats:italic>vice versa<\/jats:italic>. The primary causal estimates were obtained using the Inverse Variance Weighting Method (IVW), and the robustness of the results was evaluated through a series of sensitivity analyses.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The study found a positive impact of genetically predicted IBD on breast cancer (OR = 1.047; 95% CI:1.009\u20131.087; <jats:italic>p<\/jats:italic> = 0.014); in the analysis of IBD subtypes, genetically predicted Crohn\u2019s Disease (CD) also had a positive effect on breast cancer (OR = 1.044; 95% CI:1.015\u20131.073; <jats:italic>p<\/jats:italic> = 0.002), but genetically predicted Ulcerative Colitis (UC) did not show a significant effect on breast cancer (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). The reverse Mendelian Randomization analysis indicated that genetically predicted breast cancer promoted the overall occurrence of IBD (OR = 1.112; 95% CI:1.022\u20131.211; <jats:italic>p<\/jats:italic> = 0.014); however, genetically predicted breast cancer did not show a significant correlation with IBD subtypes (CD and UC) (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Genetic predictions indicate a positive effect of Crohn\u2019s Disease (CD) on the risk of Estrogen Receptor-Positive Breast Cancer (ER + BC), with (OR = 1.021; 95% CI:1.002\u20131.040; <jats:italic>p<\/jats:italic> = 0.002). Furthermore, a reverse Mendelian randomization analysis reveals that genetically predicted ER + BC contributes to the increased incidence of ulcerative colitis (UC), as indicated by (OR = 1.098; 95% CI:1.032\u20131.168; <jats:italic>p<\/jats:italic> = 0.003). In contrast, genetically predicted Estrogen Receptor-Negative Breast Cancer (ER-BC) has been shown to promote the overall occurrence of inflammatory bowel disease (IBD), with (OR = 1.153; 95% CI:1.008\u20131.319; <jats:italic>p<\/jats:italic> = 0.037). However, bidirectional two-sample Mendelian randomization analyses between other pairs did not reveal any significant associations (<jats:italic>p<\/jats:italic> &amp;gt; 0.05).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study elucidates the bidirectional causal association between breast cancer and inflammatory bowel disease, highlighting the necessity of screening for IBD in breast cancer patients and for breast cancer in IBD patients in clinical settings.<\/jats:p>","DOI":"10.3389\/fgene.2024.1392341","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T05:11:35Z","timestamp":1721711495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The causal association between inflammatory bowel disease and breast cancer: a bidirectional two-sample Mendelian randomization study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yulai","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"a041302","DOI":"10.1101\/cshperspect.a041302","article-title":"Mendelian randomization","volume":"12","author":"Birney","year":"2022","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/ajpa.24750","article-title":"What can Mendelian randomization contribute to biological anthropology?","volume":"181","author":"Bonilla","year":"2023","journal-title":"Am. J. Biol. Anthropol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","article-title":"Meta-analysis and Mendelian randomization: a review","volume":"10","author":"Bowden","year":"2019","journal-title":"Res. Synth. Methods"},{"key":"B4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","article-title":"Mendelian randomisation for mediation analysis: current methods and challenges for implementation","volume":"36","author":"Carter","year":"2021","journal-title":"Eur. J. Epidemiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1097\/MIB.0000000000000063","article-title":"Linking immunity, epigenetics, and cancer in inflammatory bowel disease","volume":"20","author":"D\u00e4britz","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40291-023-00678-7","article-title":"The genetics of inflammatory bowel disease","volume":"28","author":"El Hadad","year":"2024","journal-title":"Mol. Diagn Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12916-023-03096-y","article-title":"Causal association between inflammatory bowel disease and 32 site-specific extracolonic cancers: a Mendelian randomization study","volume":"21","author":"Gao","year":"2023","journal-title":"BMC Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.3748\/wjg.v26.i28.3998","article-title":"Secondary causes of inflammatory bowel diseases","volume":"26","author":"Ghouri","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CEJ.0000000000000667","article-title":"Inflammatory bowel disease and risk of breast cancer: a meta-analysis of cohort studies","volume":"31","author":"Gong","year":"2022","journal-title":"Eur. J. Cancer Prev."},{"key":"B12","first-page":"416","article-title":"Inflammatory bowel disease: a concise review","volume":"76","author":"Hemmer","year":"2023","journal-title":"S. D. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"13599","DOI":"10.1002\/cam4.6057","article-title":"Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: a two-sample Mendelian randomization analysis of European and East Asian populations","volume":"12","author":"Huang","year":"2023","journal-title":"Cancer Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br. J. Hosp. Med. (Lond)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"151992","DOI":"10.1016\/j.semarthrit.2022.151992","article-title":"Rheumatoid arthritis and inflammatory bowel disease: a bidirectional two-sample Mendelian randomization study","volume":"55","author":"Meisinger","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/medicina58050567","article-title":"Inflammatory bowel disease: clinical diagnosis and surgical treatment-overview","volume":"58","author":"M\u2019koma","year":"2022","journal-title":"Med. Kaunas."},{"key":"B17","doi-asserted-by":"publisher","first-page":"n2233","DOI":"10.1136\/bmj.n2233","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration","volume":"375","author":"Skrivankova","year":"","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"","journal-title":"Jama"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PAP.0000000000000232","article-title":"Molecular classification of breast cancer","volume":"27","author":"Tsang","year":"2020","journal-title":"Adv. Anat. Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/jcpe.13782","article-title":"Association between inflammatory bowel disease and periodontitis: a bidirectional two-sample Mendelian randomization study","volume":"50","author":"Wang","year":"2023","journal-title":"J. Clin. Periodontol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","article-title":"DNMT1: a key drug target in triple-negative breast cancer","volume":"72","author":"Wong","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1275913","DOI":"10.3389\/fonc.2023.1275913","article-title":"Appraising the causal association between Crohn's disease and breast cancer: a Mendelian randomization study","volume":"13","author":"Yu","year":"2023","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12935-022-02463-8","article-title":"DNMT1 facilitates growth of breast cancer by inducing MEG3 hyper-methylation","volume":"22","author":"Zhu","year":"2022","journal-title":"Cancer Cell Int."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1392341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T05:11:38Z","timestamp":1721711498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2024.1392341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":23,"alternative-id":["10.3389\/fgene.2024.1392341"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2024.1392341","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"article-number":"1392341"}}